Lonza announces first GMP batch completion at next-generation mammalian manufacturing facility in US
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
New research labs and process development services to enable next generation therapeutics
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Subscribe To Our Newsletter & Stay Updated